Loading...
  • patients
  • However, despite significant advances in the availability of more physiological insulin preparations, insulin delivery devices including continuous subcutaneous insulin infusion (CSII) pumps and continuous glucose monitoring (CGM) systems, most patients fail to achieve glycemic targets. (touchendocrinology.com)
  • Studies show that synthetic, genetically modified insulin could be to blame for a number of complications in diabetes patients. (greenmedinfo.com)
  • Dr. Schauer cited a 2014 comparison of composite complication rates for surgeries undergone by patients with type 2 diabetes. (endocrineweb.com)
  • Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. (semanticscholar.org)
  • Our findings are important because they underscore the need for further research that examines the impact of exercise and healthy diet on cancer risk specifically in patients with or at risk for diabetes," Lega said in a journal news release. (drugs.com)
  • Yet the vast majority of patients with type 2 diabetes do not achieve adequate control of their blood glucose levels, particularly their post-meal glucose. (drugs.com)
  • Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. (annals.org)
  • In patients with uncontrolled type 2 diabetes who are receiving metformin therapy, is weekly dulaglutide noninferior to daily liraglutide for reducing hemoglobin (Hb) A 1c levels? (annals.org)
  • Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. (cardiosmart.org)
  • Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? (cardiosmart.org)
  • Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. (cardiosmart.org)
  • A double-blind, active-controlled study enrolled 686 patients with type 2 diabetes to study the efficacy and safety of empagliflozin 10 mg or 25 mg in combination with linagliptin 5 mg vs. the individual components. (clinicaladvisor.com)
  • Patients inadequately controlled on ≥1,500mg of metformin/day entered a single-blind placebo run-in period for 2 weeks. (clinicaladvisor.com)
  • Canaglifozin found to significantly lower the risk for heart failure in type 2 diabetes patients. (medindia.net)
  • Type 2 diabetes patients were assessed for the risk of heart failure, particularly in patients with established or high risk for cardiovascular disease. (medindia.net)
  • The purpose of the Patient Guide to Insulin is to educate patients, parents, and caregivers about insulin treatment of diabetes. (endocrineweb.com)
  • ABCG8 polymorphisms and renal disease in type 2 diabetic patients. (semanticscholar.org)
  • pancreatic
  • The antidiabetic potential of flavonoids are mainly through their modulatory effects on glucose transporter by enhancing GLUT-2 expression in pancreatic β cells and increasing expression and promoting translocation of GLUT-4 via PI3K/AKT, CAP/Cb1/TC10 and AMPK pathways. (ijbs.com)
  • placebo
  • This will include a 1-week screening period, an up to 13-week wash-off/titration/dose stabilization period, a 2-week placebo run-in period, a 104-week double-blind, active comparator-controlled treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug. (clinicaltrials.gov)
  • Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104. (clinicaltrials.gov)
  • Glyxambi
  • Glyxambi (empagliflozin/linagliptin) is now approved in addition to a healthy meal plan and physical activity, for the treatment of type 2 diabetes . (endocrineweb.com)
  • Glyxambi, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, is the first ever combination treatment containing the diabetes medications empagliflozin and linagliptin in a once daily pill. (endocrineweb.com)
  • U.S. FDA Approves First-In-Class Glyxambi (Empagliflozin/Linagliptin) Tablets For Adults With Type 2 Diabetes. (endocrineweb.com)
  • molecular
  • This review highlights the recent findings on beneficial effects of flavonoids in the management of diabetes with particular emphasis on the investigations that explore the role of these compounds in modulating glucose transporter proteins at cellular and molecular level. (ijbs.com)
  • kidneys
  • T 2 DM affects several major organs, including heart, blood vessels, nerves, eyes and kidneys leading to disabling or even life-threatening complications such as cardiac dysfunction, atherosclerosis, and nephropathy [ 7 ]. (ijbs.com)
  • hypoglycemia
  • 5 There are periods of hyperglycemia and hypoglycemia with marked daily fluctuations in blood glucose. (touchendocrinology.com)
  • Type 2 diabetics who are taking glucose-lowering medications are at especially great risk of hypoglycemia, or very low blood sugar levels, and therefore need to remain mindful of potential side effects of supplements and herbs. (livestrong.com)
  • incidence
  • New research finds that a change to a low-carb Mediterranean Diet can significantly reverse and reduce type 2 diabetes incidence, even more than a low-fat diet - which also reduces risk. (greenmedinfo.com)
  • Recent large-scale clinical trials have shown that frequent lifestyle advice, delivered by a health professional, is effective at reducing diabetes incidence in people at high risk. (drugs.com)
  • hyperglycemia
  • Diabetes mellitus (DM) is a metabolic diseases characterized by hyperglycemia due to insufficient or inefficient insulin secretory response. (ijbs.com)
  • Flavonoids have antioxidative properties which protect the body against the deleterious effects of hyperglycemia in T 2 DM, through acting on the biological targets such as α-glucosidase, glucose co-transporter or aldose reductase. (ijbs.com)
  • drugs
  • These antioxidants have been proposed as potential anti-diabetic drugs by acting as biological targets involved in T 2 DM development. (ijbs.com)
  • concentrations
  • Dark green leafy vegetables contain magnesium, which may decrease fasting glucose and improve HDL concentrations. (livestrong.com)
  • 2) Magnesium: A meta-analysis (a study that combines results of multiple independent studies) found that oral magnesium supplementation may decrease fasting glucose and improve HDL (high-density lipoprotein, or good cholesterol) concentrations. (livestrong.com)